Cellular Reprogramming

Epigenetic reprogramming is emerging as a key approach in longevity tech, aiming to reverse cellular aging and extend healthy lifespans.

Themes

AI-Driven Transformation , Navigating Global Uncertainty

Timeframe

long-term

Subcategories

Corporate Strategy Healthcare Innovation Innovation Management Risk Management

Impact areas

Biotechnology Healthcare Longevity

Detailed Analysis

Rapidly aging populations and rising healthcare costs are driving interest in longevity technologies. Cellular and epigenetic reprogramming, which alters gene expression without changing genes themselves, is a promising approach to reverse the effects of cellular aging. This technology has the potential to treat age-related conditions and significantly impact healthcare spending.

Context Signals

Turn Bio's licensing agreement with HanAll Biopharma Investment in longevity tech startups like Retro Biosciences, NewLimit, and Altos Labs Growing headcounts in cellular and epigenetic reprogramming companies

Edge

Personalized epigenetic therapies for age-related diseases Integration of epigenetic reprogramming with other longevity interventions Societal implications of significantly extended lifespans

Click to access the source report